S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|ImmunoGen, Inc. Announces Discontinuation of IMGN901 Study in Small-Cell Lung Cancer (SCLC) (2013/11/5)|
|ImmunoGen, Inc. Announces SAR566658 Clinical Findings Reported at AACR-NCI-EORTC Conference (2013/10/20)|
|ImmunoGen, Inc. Announces Presentations at Upcoming AACR-NCI-EORTC Anticancer Conference (2013/10/15)|
|ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2014 Financial Results (2013/10/18)|
|ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update ()|
|ImmunoGen, Inc. Announces FDA Acceptance of IND for Company’s Novel EGFR-Targeting ADC, IMGN289 ()|
|ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences ()|
|ImmunoGen, Inc. Initiates Phase I Testing of Its EGFR-Targeting ADC, IMGN289 (2013/11/5)|
|ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla® in the European Union (2013/11/20)|
|ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress (2013/9/28)|
Click above to view more mutual fund data and stats for imgn - Immunogen, Inc..